A Randomized, Placebo-Controlled, Phase 3 Study to Evaluate the Ability of a Novel Genomic Biomarker to Predict Survival of Treatment Naïve, High Risk Subjects with Diffuse Large B-Cell Lymphoma Treated with R-CHOP plus Enzastaurin
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
A Phase III, Double-Blind, Placebo Controlled, Multicenter, Randomized Study of Pracinostat in Combination with AZAcitidine in Patients > 18 Years with Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Standard Induction Chemotherapy
An Open-Label Phase 4 Study of Carfilzomib Plus Dexamethsone to Assess Tolerability and Adherence in Subjects with Relapsed or Refractory Multiple Myeloma at US Oncology Centers